First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1029 in Patients With Malignant Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs GEN-1029 (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Genmab
- 17 Nov 2019 Planned number of patients changed from 206 to 520.
- 24 Sep 2019 This trial has been suspended in Spain, according to European Clinical Trials Database record.
- 26 Mar 2018 New trial record